

SHORT STATURE AND SKELETAL DYSPLASIA DG 2.16 (354 genes)

Releasedate: 07-06-2019

| Gene | Median coverage | % covered > 10x | % covered > 20x | Associated phenotype description and OMIM disease ID |
|----------|-----------------|-----------------|-----------------|--|
| ABCC9 | 142,6 | 100.0% | 99.7% | Atrial fibrillation, familial, 12, 614050 Cardiomyopathy, dilated, 10, 608569 Hypertrichotic osteochondrodysplasia, 239850 |
| ACAN | 121,3 | 94.6% | 89.1% | ?Spondyloepiphyseal dysplasia, Kimberley type, 608361 Short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 |
| ACP5 | 172,6 | 100.0% | 99.6% | Spondyloenchondrodysplasia with immune dysregulation, 607944 |
| ACTB | 80,5 | 100.0% | 99.7% | ?Dystonia, juvenile-onset, 607371 Baraitser-Winter syndrome 1, 243310 |
| ACVR1 | 136,9 | 100.0% | 99.9% | Fibrodysplasia ossificans progressiva, 135100 |
| ADAMTS10 | 122,8 | 100.0% | 99.8% | Weill-Marchesani syndrome 1, recessive, 277600 |
| ADAMTS17 | 109,2 | 97.6% | 92.3% | Weill-Marchesani 4 syndrome, recessive, 613195 |
| ADAMTSL2 | 115,9 | 99.0% | 96.3% | Geleophysic dysplasia 1, 231050 |
| AGA | 142,7 | 100.0% | 100.0% | Aspartylglucosaminuria, 208400 |
| AGPS | 75,4 | 99.5% | 97.8% | Rhizomelic chondrodysplasia punctata, type 3, 600121 |
| ALG12 | 155,7 | 100.0% | 99.9% | Congenital disorder of glycosylation, type Ig, 607143 |
| ALG3 | 106,5 | 100.0% | 99.9% | Congenital disorder of glycosylation, type Id, 601110 |
| ALG9 | 113 | 100.0% | 99.6% | Congenital disorder of glycosylation, type II, 608776 Gillessen-Kaesbach-Nishimura syndrome, 263210 |
| ALMS1 | 172,8 | 100.0% | 99.7% | Alstrom syndrome, 203800 |
| ALPL | 154,8 | 100.0% | 99.7% | Hypophosphatasia, adult, 146300 Hypophosphatasia, childhood, 241510 Hypophosphatasia, infantile, 241500 Odontohypophosphatasia, 146300 |
| AMER1 | 98,2 | 99.8% | 98.9% | Osteopathia striata with cranial sclerosis, 300373 |
| AMMECR1 | 97,4 | 99.8% | 98.9% | Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis, 300990 |

| | | | | |
|---------|-------|--------|--------|--|
| ANKH | 111,6 | 100.0% | 99.9% | Chondrocalcinosis 2, 118600 Craniometaphyseal dysplasia, 123000 |
| ANKRD11 | 119,6 | 99.2% | 97.1% | KBG syndrome, 148050 |
| ANOS5 | 131 | 99.6% | 97.3% | Gnathodiaphyseal dysplasia, 166260 Miyoshi muscular dystrophy 3, 613319 Muscular dystrophy, limb-girdle, autosomal recessive 12, 611307 |
| ARSB | 109,4 | 99.9% | 98.9% | Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 |
| ARSE | 80,5 | 97.9% | 89.2% | Chondrodysplasia punctata, X-linked recessive, 302950 |
| B3GALT6 | 81,7 | 82.6% | 77.6% | Ehlers-Danlos syndrome, spondylodysplastic type, 2, 615349 Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 |
| B3GAT3 | 121 | 99.6% | 96.5% | Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 |
| B4GALT7 | 123,9 | 99.8% | 98.1% | Ehlers-Danlos syndrome, spondylodysplastic type, 1, 130070 |
| BMP1 | 152,7 | 100.0% | 100.0% | Osteogenesis imperfecta, type XIII, 614856 |
| BMP2 | 163,4 | 100.0% | 100.0% | Brachydactyly, type A2, 112600 Short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies, 617877 {HFE hemochromatosis, modifier of}, 235200 |
| BMPER | 127,1 | 100.0% | 99.5% | Diaphanospondylodysostosis, 608022 |
| BMPR1B | 139,4 | 100.0% | 100.0% | Acromesomelic dysplasia, Demirhan type, 609441 Brachydactyly, type A1, D, 616849 Brachydactyly, type A2, 112600 |
| BRAF | 72,5 | 92.4% | 80.2% | Adenocarcinoma of lung, somatic, 211980 Cardiofaciocutaneous syndrome, 115150 Colorectal cancer, somatic, 0 LEOPARD syndrome 3, 613707 Melanoma, malignant, somatic, 0 Nonsmall cell lung cancer, somatic, 0 Noonan syndrome 7, 613706 |
| BRF1 | 109 | 99.8% | 98.1% | Cerebellofaciodental syndrome, 616202 |
| BTK | 98 | 99.9% | 99.0% | Agammaglobulinemia, X-linked 1, 300755 Isolated growth hormone deficiency, type III, with agammaglobulinemia, 307200 |
| C21orf2 | NC | NC | NC | Retinal dystrophy with macular staphyloma, 617547 Spondylometaphyseal dysplasia, axial, 602271 |
| C5orf42 | NC | NC | NC | Joubert syndrome 17, 614615 Orofaciodigital syndrome VI, 277170 |
| CA2 | 137,4 | 100.0% | 99.9% | Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 |

| | | | | |
|---------|-------|--------|--------|---|
| CANT1 | 144,9 | 100.0% | 100.0% | Desbuquois dysplasia 1, 251450 Epiphyseal dysplasia, multiple, 7, 617719 |
| CBL | 126 | 97.3% | 97.0% | ?Juvenile myelomonocytic leukemia, 607785 Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 |
| CCDC8 | 186,9 | 100.0% | 100.0% | 3-M syndrome 3, 614205 |
| CDC42 | 90,2 | 97.6% | 89.1% | Takenouchi-Kosaki syndrome, 616737 |
| CDC45 | 138,9 | 99.6% | 98.1% | Meier-Gorlin syndrome 7, 617063 |
| CDC6 | 139,4 | 99.9% | 99.8% | ?Meier-Gorlin syndrome 5, 613805 |
| CDKN1C | 100,1 | 89.8% | 81.7% | Beckwith-Wiedemann syndrome, 130650 IMAGE syndrome, 614732 |
| CDT1 | 130,9 | 100.0% | 99.9% | Meier-Gorlin syndrome 4, 613804 |
| CEP120 | 131,7 | 100.0% | 99.4% | Joubert syndrome 31, 617761 Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 |
| CHST3 | 133,8 | 100.0% | 100.0% | Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 |
| CLCN5 | 104,3 | 99.7% | 96.5% | Dent disease, 300009 Hypophosphatemic rickets, 300554 Nephrolithiasis, type I, 310468 Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 |
| CLCN7 | 146,7 | 99.8% | 98.7% | Osteopetrosis, autosomal dominant 2, 166600 Osteopetrosis, autosomal recessive 4, 611490 |
| COG1 | 108,4 | 100.0% | 99.9% | Congenital disorder of glycosylation, type IIg, 611209 |
| COL10A1 | 106,8 | 100.0% | 99.9% | Metaphyseal chondrodysplasia, Schmid type, 156500 |
| COL11A1 | 96,6 | 97.9% | 94.0% | Fibrochondrogenesis 1, 228520 Marshall syndrome, 154780 Stickler syndrome, type II, 604841 {Lumbar disc herniation, susceptibility to}, 603932 |
| COL11A2 | 111,6 | 100.0% | 99.4% | Deafness, autosomal dominant 13, 601868 Deafness, autosomal recessive 53, 609706 Fibrochondrogenesis 2, 614524 Otospondylomegaepiphyseal dysplasia, autosomal dominant, 184840 Otospondylomegaepiphyseal dysplasia, autosomal recessive, 215150 |

| | | | | |
|---------|-------|--------|--------|---|
| COL1A1 | 141 | 99.8% | 98.4% | Caffey disease, 114000 Ehlers-Danlos syndrome, arthrochalasia type, 1, 130060 Osteogenesis imperfecta, type I, 166200 Osteogenesis imperfecta, type II, 166210 Osteogenesis imperfecta, type III, 259420 Osteogenesis imperfecta, type IV, 166220 {Bone mineral density variation QTL, osteoporosis}, 166710 |
| COL1A2 | 93,3 | 98.5% | 94.6% | Ehlers-Danlos syndrome, arthrochalasia type, 2, 617821 Ehlers-Danlos syndrome, cardiac valvular type, 225320 Osteogenesis imperfecta, type II, 166210 Osteogenesis imperfecta, type III, 259420 Osteogenesis imperfecta, type IV, 166220 {Osteoporosis, postmenopausal}, 166710 |
| COL27A1 | 142,2 | 99.9% | 99.2% | Steel syndrome, 615155 |
| COL2A1 | 112,2 | 100.0% | 99.7% | Achondrogenesis, type II or hypochondrogenesis, 200610 Avascular necrosis of the femoral head, 608805 Czech dysplasia, 609162 Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 Kniest dysplasia, 156550 Legg-Calve-Perthes disease, 150600 Osteoarthritis with mild chondrodysplasia, 604864 Platyspondylic skeletal dysplasia, Torrance type, 151210 SED congenita, 183900 SMED Strudwick type, 184250 Spondyloepiphyseal dysplasia, Stanescu type, 616583 Spondyloperipheral dysplasia, 271700 Stickler syndrome, type I, nonsyndromic ocular, 609508 Stickler syndrome, type I, 108300 Vitreoretinopathy with phalangeal epiphyseal dysplasia, 0 |
| COL9A1 | 132,3 | 100.0% | 99.7% | ?Epiphyseal dysplasia, multiple, 6, 614135 Stickler syndrome, type IV, 614134 |
| COL9A2 | 95,2 | 99.9% | 98.8% | ?Stickler syndrome, type V, 614284 Epiphyseal dysplasia, multiple, 2, 600204 |
| COL9A3 | 107,8 | 99.6% | 96.8% | Epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 {Intervertebral disc disease, susceptibility to}, 603932 |
| COLEC11 | 180,6 | 100.0% | 100.0% | 3MC syndrome 2, 265050 |

| | | | | |
|------------|-------|--------|--------|--|
| COMP | 132 | 95.8% | 92.8% | Epiphyseal dysplasia, multiple, 1, 132400 Pseudoachondroplasia, 177170 |
| CREB3L1 | 135,8 | 100.0% | 99.8% | Osteogenesis imperfecta, type XVI, 616229 |
| CREBBP | 110,7 | 99.4% | 97.0% | Menke-Hennekam syndrome 1, 618332 Rubinstein-Taybi syndrome 1, 180849 |
| CRTAP | 120,2 | 100.0% | 99.1% | Osteogenesis imperfecta, type VII, 610682 |
| CSF1R | 113,3 | 99.9% | 99.1% | Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 |
| CSGALNACT1 | 153 | 100.0% | 99.6% | No OMIM phenotype Skeletal dysplasia and joint laxity (Vodopiutz (2017) Hum Mutat 38,34) ?Hemi-facial palsy (Saigoh (2011) J Hum Genet 56,143) ?Neuropathy, hereditary motor and sensory (Saigoh (2011) J Hum Genet 56,143) |
| CTSA | 132,9 | 100.0% | 99.9% | Galactosialidosis, 256540 |
| CTSK | 86,3 | 100.0% | 99.8% | Pycnodysostosis, 265800 |
| CUL7 | 129,2 | 100.0% | 99.8% | 3-M syndrome 1, 273750 |
| CYP26B1 | 168,7 | 100.0% | 100.0% | Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 |
| CYP27B1 | 147,1 | 100.0% | 99.7% | Vitamin D-dependent rickets, type I, 264700 |
| DDR2 | 115,8 | 100.0% | 99.3% | Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 Warburg-Cinotti syndrome, 618175 |
| DHCR24 | 155,8 | 100.0% | 99.9% | Desmosterolosis, 602398 |
| DLL3 | 108,5 | 96.7% | 92.5% | Spondylocostal dysostosis 1, autosomal recessive, 277300 |
| DLX3 | 146,7 | 100.0% | 99.0% | Amelogenesis imperfecta, type IV, 104510 Trichodontoosseous syndrome, 190320 |
| DMP1 | 133 | 100.0% | 99.9% | Hypophosphatemic rickets, AR, 241520 |
| DNMT3A | 122,9 | 99.7% | 98.2% | Acute myeloid leukemia, somatic, 601626 Tatton-Brown-Rahman syndrome, 615879 |
| DONSON | 90,2 | 99.0% | 92.4% | Microcephaly, short stature, and limb abnormalities, 617604 Microcephaly-micromelia syndrome, 251230 |
| DPM1 | 134,7 | 95.2% | 88.2% | Congenital disorder of glycosylation, type Ie, 608799 |
| DVL1 | 140,8 | 98.6% | 95.9% | Robinow syndrome, autosomal dominant 2, 616331 |
| DVL3 | 186 | 100.0% | 100.0% | Robinow syndrome, autosomal dominant 3, 616894 |
| DYM | 103,3 | 97.4% | 95.5% | Dyggve-Melchior-Clausen disease, 223800 Smith-McCort dysplasia, 607326 |
| DYNC2H1 | 102,2 | 98.8% | 95.5% | Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 |
| DYNC2LI1 | 95,4 | 99.7% | 97.0% | Short-rib thoracic dysplasia 15 with polydactyly, 617088 |

| | | | | |
|---------|-------|--------|--------|--|
| EBP | 63,2 | 99.5% | 95.2% | Chondrodysplasia punctata, X-linked dominant, 302960 MEND syndrome, 300960 |
| EFL1 | 150,5 | 99.5% | 98.1% | Shwachman-Diamond syndrome 2, 617941 |
| EIF2AK3 | 134,2 | 99.5% | 96.3% | Wolcott-Rallison syndrome, 226980 |
| ENPP1 | 129,2 | 97.5% | 93.3% | Arterial calcification, generalized, of infancy, 1, 208000 Cole disease, 615522 Hypophosphatemic rickets, autosomal recessive, 2, 613312 {Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 {Obesity, susceptibility to}, 601665 |
| ESCO2 | 115,6 | 99.4% | 97.3% | Roberts syndrome, 268300 SC phocomelia syndrome, 269000 |
| EVC | 106,3 | 95.9% | 92.4% | ?Weyers acrofacial dysostosis, 193530 Ellis-van Creveld syndrome, 225500 |
| EVC2 | 110,2 | 99.4% | 96.3% | Ellis-van Creveld syndrome, 225500 Weyers acrofacial dysostosis, 193530 |
| EXT1 | 88,6 | 99.6% | 98.0% | Chondrosarcoma, 215300 Exostoses, multiple, type 1, 133700 |
| EXT2 | 118 | 99.9% | 99.1% | ?Seizures, scoliosis, and macrocephaly syndrome, 616682 Exostoses, multiple, type 2, 133701 |
| EXTL3 | 184,1 | 100.0% | 100.0% | Immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 |
| FAM111A | 232,1 | 100.0% | 99.5% | Gracile bone dysplasia, 602361 Kenny-Caffey syndrome, type 2, 127000 |
| FAM20C | 145,2 | 100.0% | 100.0% | Raine syndrome, 259775 |
| FBN1 | 137,1 | 100.0% | 99.8% | Acromicric dysplasia, 102370 Ectopia lentis, familial, 129600 Geleophysic dysplasia 2, 614185 Marfan lipodystrophy syndrome, 616914 Marfan syndrome, 154700 MASS syndrome, 604308 Stiff skin syndrome, 184900 Weill-Marchesani syndrome 2, dominant, 608328 |
| FERMT3 | 144,9 | 100.0% | 99.9% | Leukocyte adhesion deficiency, type III, 612840 |
| FGD1 | 86,7 | 98.4% | 93.0% | Aarskog-Scott syndrome, 305400 Mental retardation, X-linked syndromic 16, 305400 |

| | | | | |
|-------|-------|--------|--------|--|
| FGF23 | 122,3 | 99.7% | 97.7% | Hypophosphatemic rickets, autosomal dominant, 193100 Osteomalacia, tumor-induced, 0 Tumoral calcinosis, hyperphosphatemic, familial, 2, 617993 |
| FGF8 | 130 | 97.9% | 86.8% | Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 |
| FGF9 | 153,5 | 100.0% | 100.0% | Multiple synostoses syndrome 3, 612961 |
| FGFR1 | 122,6 | 100.0% | 99.6% | Encephalocraniocutaneous lipomatosis, 613001 Hartsfield syndrome, 615465 Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 Jackson-Weiss syndrome, 123150 Osteoglophonic dysplasia, 166250 Pfeiffer syndrome, 101600 Trigonocephaly 1, 190440 |
| FGFR2 | 113,1 | 97.7% | 96.8% | Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 Apert syndrome, 101200 Beare-Stevenson cutis gyrata syndrome, 123790 Bent bone dysplasia syndrome, 614592 Craniofacial-skeletal-dermatologic dysplasia, 101600 Craniosynostosis, nonspecific, 0 Crouzon syndrome, 123500 Gastric cancer, somatic, 613659 Jackson-Weiss syndrome, 123150 LADD syndrome, 149730 Pfeiffer syndrome, 101600 Saethre-Chotzen syndrome, 101400 Scaphocephaly and Axenfeld-Rieger anomaly, 0 Scaphocephaly, maxillary retrusion, and mental retardation, 609579 |
| FGFR3 | 138,5 | 100.0% | 99.6% | Achondroplasia, 100800 Bladder cancer, somatic, 109800 CATSHL syndrome, 610474 Cervical cancer, somatic, 603956 Colorectal cancer, somatic, 114500 Crouzon syndrome with acanthosis nigricans, 612247 Hypochondroplasia, 146000 LADD syndrome, 149730 Muenke syndrome, 602849 Nevus, epidermal, somatic, 162900 SADDAN, 616482 Spermatocytic seminoma, somatic, 273300 |

| | | | | |
|--------|-------|--------|--------|--|
| | | | | Thanatophoric dysplasia, type I, 187600 Thanatophoric dysplasia, type II, 187601 |
| FIG4 | 157,5 | 100.0% | 99.6% | ?Polymicrogyria, bilateral temporooccipital, 612691 Amyotrophic lateral sclerosis 11, 612577 Charcot-Marie-Tooth disease, type 4J, 611228 Yunis-Varon syndrome, 216340 |
| FKBP10 | 157,5 | 99.5% | 97.3% | Bruck syndrome 1, 259450 Osteogenesis imperfecta, type XI, 610968 |
| FLNA | 142,7 | 100.0% | 99.9% | ?FG syndrome 2, 300321 Cardiac valvular dysplasia, X-linked, 314400 Congenital short bowel syndrome, 300048 Frontometaphyseal dysplasia 1, 305620 Heterotopia, periventricular, 1, 300049 Intestinal pseudoobstruction, neuronal, 300048 Melnick-Needles syndrome, 309350 Otopalatodigital syndrome, type I, 311300 Otopalatodigital syndrome, type II, 304120 Terminal osseous dysplasia, 300244 |
| FLNB | 123,6 | 99.7% | 98.7% | Atelosteogenesis, type I, 108720 Atelosteogenesis, type III, 108721 Boomerang dysplasia, 112310 Larsen syndrome, 150250 Spondylometatarsal synostosis syndrome, 272460 |
| FN1 | 106 | 99.9% | 98.9% | Glomerulopathy with fibronectin deposits 2, 601894 Plasma fibronectin deficiency, 614101 Spondylometaphyseal dysplasia, corner fracture type, 184255 |
| FUCA1 | 125,9 | 100.0% | 99.9% | Fucosidosis, 230000 |
| FZD2 | 179,4 | 99.7% | 97.8% | Omodysplasia 2, 164745 |
| GALNS | 108,3 | 100.0% | 99.3% | Mucopolysaccharidosis IVA, 253000 |
| GALNT3 | 125,8 | 99.9% | 98.7% | Tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 |
| GDF3 | 127,9 | 100.0% | 100.0% | Klippel-Feil syndrome 3, autosomal dominant, 613702 Microphthalmia with coloboma 6, 613703 Microphthalmia, isolated 7, 613704 |

| | | | | |
|-------|-------|--------|--------|---|
| GDF5 | 169,6 | 100.0% | 100.0% | ?Acromesomelic dysplasia, Hunter-Thompson type, 201250 Brachydactyly, type A1, C, 615072 Brachydactyly, type A2, 112600 Brachydactyly, type C, 113100 Chondrodysplasia, Grebe type, 200700 Du Pan syndrome, 228900 Multiple synostoses syndrome 2, 610017 Symphalangism, proximal, 1B, 615298 {Osteoarthritis-5}, 612400 |
| GDF6 | 156,3 | 100.0% | 100.0% | Klippel-Feil syndrome 1, autosomal dominant, 118100 Leber congenital amaurosis 17, 615360 Microphthalmia with coloboma 6, digenic, 613703 Microphthalmia, isolated 4, 613094 Multiple synostoses syndrome 4, 617898 |
| GH1 | 159,5 | 100.0% | 100.0% | Growth hormone deficiency, isolated, type IA, 262400 Growth hormone deficiency, isolated, type IB, 612781 Growth hormone deficiency, isolated, type II, 173100 Kowarski syndrome, 262650 |
| GHR | 150,6 | 99.5% | 99.4% | Growth hormone insensitivity, partial, 604271 Increased responsiveness to growth hormone, 604271 Laron dwarfism, 262500 {Hypercholesterolemia, familial, modifier of}, 143890 |
| GHRHR | 108,1 | 96.0% | 95.2% | Growth hormone deficiency, isolated, type IV, 618157 |
| GHSR | 173,6 | 98.7% | 95.2% | Growth hormone deficiency, isolated partial, 615925 |
| GJA1 | 156,2 | 100.0% | 100.0% | Atrioventricular septal defect 3, 600309 Craniometaphyseal dysplasia, autosomal recessive, 218400 Erythrokeratoderma variabilis et progressiva 3, 617525 Hypoplastic left heart syndrome 1, 241550 Oculodentodigital dysplasia, 164200 Oculodentodigital dysplasia, autosomal recessive, 257850 Palmoplantar keratoderma with congenital alopecia, 104100 Syndactyly, type III, 186100 |
| GLB1 | 82,6 | 99.7% | 95.4% | GM1-gangliosidosis, type I, 230500 GM1-gangliosidosis, type II, 230600 GM1-gangliosidosis, type III, 230650 Mucopolysaccharidosis type IVB (Morquio), 253010 |
| GLI2 | 158,2 | 100.0% | 100.0% | Culler-Jones syndrome, 615849 Holoprosencephaly 9, 610829 |

| | | | | |
|--------|-------|--------|--------|--|
| GLI3 | 139,5 | 100.0% | 99.3% | Greig cephalopolysyndactyly syndrome, 175700 Pallister-Hall syndrome, 146510 Polydactyly, postaxial, types A1 and B, 174200 Polydactyly, preaxial, type IV, 174700 {Hypothalamic hamartomas, somatic}, 241800 |
| GMNN | 124,4 | 99.7% | 97.9% | Meier-Gorlin syndrome 6, 616835 |
| GNAS | 211,3 | 100.0% | 100.0% | ACTH-independent macronodular adrenal hyperplasia, 219080 McCune-Albright syndrome, somatic, mosaic, 174800 Osseous heteroplasia, progressive, 166350 Pituitary adenoma 3, multiple types, somatic, 617686 Pseudohypoparathyroidism Ia, 103580 Pseudohypoparathyroidism Ib, 603233 Pseudohypoparathyroidism Ic, 612462 Pseudopseudohypoparathyroidism, 612463 |
| GNPAT | 127,2 | 99.5% | 96.8% | Rhizomelic chondrodysplasia punctata, type 2, 222765 |
| GNPTAB | 148 | 100.0% | 99.3% | Mucopolipidosis II alpha/beta, 252500 Mucopolipidosis III alpha/beta, 252600 |
| GNPTG | 177,6 | 100.0% | 98.5% | Mucopolipidosis III gamma, 252605 |
| GNS | 94,5 | 99.6% | 95.2% | Mucopolysaccharidosis type IIID, 252940 |
| GORAB | 165,7 | 100.0% | 98.9% | Geroderma osteodysplasticum, 231070 |
| GPC3 | 75,7 | 98.7% | 92.7% | Simpson-Golabi-Behmel syndrome, type 1, 312870 Wilms tumor, somatic, 194070 |
| GPC6 | 126,6 | 100.0% | 100.0% | Omodysplasia 1, 258315 |
| GPR161 | 170,5 | 100.0% | 100.0% | No OMIM phenotype Pituitary stalk interruption syndrome (Karaca (2015) J Clin Endocrinol Metab 100,E140) |
| GPX4 | 165,9 | 94.4% | 90.7% | Spondylometaphyseal dysplasia, Sedaghatian type, 250220 |
| GUSB | 99,5 | 92.5% | 90.5% | Mucopolysaccharidosis VII, 253220 |
| HDAC4 | 119,6 | 100.0% | 99.9% | No OMIM phenotype Anorexia nervosa/bulimia nervosa (Cui (2013) J Clin Invest 123,4706) Brachydactyly mental retardation syndrome (Williams (2010) Am J Hum Genet 87, 219) ?Autism spectrum disorder (Pinto (2014) Am J Hum Genet 94, 677) |
| HES7 | 53,9 | 90.1% | 72.7% | Spondylocostal dysostosis 4, autosomal recessive, 613686 |
| HESX1 | 66,2 | 100.0% | 98.7% | Growth hormone deficiency with pituitary anomalies, 182230 Pituitary hormone deficiency, combined, 5, 182230 Septooptic dysplasia, 182230 |

| | | | | |
|--------|-------|--------|--------|--|
| HGSNAT | 98,3 | 87.2% | 86.2% | Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 Retinitis pigmentosa 73, 616544 |
| HMGA2 | 84,9 | 81.4% | 75.5% | Leiomyoma, uterine, somatic, 150699 |
| HOXA13 | 77,7 | 90.9% | 79.6% | Guttmacher syndrome, 176305 Hand-foot-uterus syndrome, 140000 |
| HPGD | 90,6 | 99.9% | 98.9% | Cranioosteoarthropathy, 259100 Digital clubbing, isolated congenital, 119900 Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 |
| HRAS | 182,3 | 100.0% | 100.0% | Bladder cancer, somatic, 109800 Congenital myopathy with excess of muscle spindles, 218040 Costello syndrome, 218040 Nevus sebaceous or woolly hair nevus, somatic, 162900 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaicism, 163200 Spitz nevus or nevus spilus, somatic, 137550 Thyroid carcinoma, follicular, somatic, 188470 |
| HSPA9 | 82,6 | 89.5% | 84.2% | Anemia, sideroblastic, 4, 182170 Even-plus syndrome, 616854 |
| HSPG2 | 119,8 | 99.5% | 98.8% | Dyssegmental dysplasia, Silverman-Handmaker type, 224410 Schwartz-Jampel syndrome, type 1, 255800 |
| HYLS1 | 156,6 | 100.0% | 100.0% | Hydrolethalus syndrome, 236680 |
| IDH1 | 78 | 89.4% | 77.3% | {Glioma, susceptibility to, somatic}, 137800 |
| IDH2 | 98,5 | 100.0% | 99.6% | D-2-hydroxyglutaric aciduria 2, 613657 |
| IDS | 100,9 | 99.9% | 97.1% | Mucopolysaccharidosis II, 309900 |
| IDUA | 148,1 | 98.9% | 94.6% | Mucopolysaccharidosis Ih, 607014 Mucopolysaccharidosis Ih/s, 607015 Mucopolysaccharidosis Is, 607016 |
| IFITM5 | 94,9 | 100.0% | 99.1% | Osteogenesis imperfecta, type V, 610967 |
| IFT122 | 120,5 | 99.9% | 99.0% | Cranioectodermal dysplasia 1, 218330 |
| IFT140 | 117,6 | 99.9% | 99.2% | Retinitis pigmentosa 80, 617781 Short-rib thoracic dysplasia 9 with or without polydactyly, 266920 |
| IFT172 | 94,5 | 100.0% | 99.4% | Retinitis pigmentosa 71, 616394 Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 |
| IFT43 | 112,4 | 100.0% | 100.0% | ?Cranioectodermal dysplasia 3, 614099 ?Retinitis pigmentosa 81, 617871 Short-rib thoracic dysplasia 18 with polydactyly, 617866 |

| | | | | |
|----------|-------|--------|--------|--|
| IIFT80 | 64,9 | 96.7% | 84.7% | Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 |
| IGF1 | 98 | 100.0% | 99.8% | Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 |
| IGF1R | 114,9 | 100.0% | 99.6% | Insulin-like growth factor I, resistance to, 270450 |
| IGF2 | 119,6 | 100.0% | 100.0% | ?Growth restriction, severe, with distinctive facies, 616489 |
| IGFALS | 108,2 | 100.0% | 99.9% | Acid-labile subunit, deficiency of, 615961 |
| IGSF1 | 69,9 | 99.2% | 93.9% | Hypothyroidism, central, and testicular enlargement, 300888 |
| IHH | 171,9 | 100.0% | 100.0% | Acrocapitofemoral dysplasia, 607778 Brachydactyly, type A1, 112500 |
| IKBKB | 110 | 99.3% | 96.4% | Immunodeficiency 15A, 618204 Immunodeficiency 15B, 615592 |
| IKBKG | 60,1 | 88.1% | 78.8% | Ectodermal dysplasia and immunodeficiency 1, 300291 Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 Immunodeficiency 33, 300636 Immunodeficiency, isolated, 300584 Incontinentia pigmenti, 308300 Invasive pneumococcal disease, recurrent isolated, 2, 300640 |
| IL2RG | 59,3 | 99.3% | 94.0% | Combined immunodeficiency, X-linked, moderate, 312863 Severe combined immunodeficiency, X-linked, 300400 |
| IMPAD1 | 170,4 | 100.0% | 99.9% | Chondrodysplasia with joint dislocations, GPAPP type, 614078 |
| INPPL1 | 127,9 | 99.8% | 98.0% | Opsismodysplasia, 258480 |
| KIAA0753 | 113,2 | 99.9% | 98.7% | ?Orofaciodigital syndrome XV, 617127 |
| KIF22 | 173,8 | 100.0% | 99.9% | Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 |
| KIF7 | 105,2 | 98.2% | 93.5% | ?Al-Gazali-Bakalinova syndrome, 607131 ?Hydroletharus syndrome 2, 614120 Acrocallosal syndrome, 200990 Joubert syndrome 12, 200990 |
| KMT2A | 133 | 100.0% | 99.9% | Leukemia, myeloid/lymphoid or mixed-lineage, 159555 Wiedemann-Steiner syndrome, 605130 |

| | | | | |
|-------|-------|--------|--------|---|
| KRAS | 67,2 | 99.4% | 97.3% | Arteriovenous malformation of the brain, somatic, 108010 Bladder cancer, somatic, 109800 Breast cancer, somatic, 114480 Cardiofaciocutaneous syndrome 2, 615278 Gastric cancer, somatic, 137215 Leukemia, acute myeloid, 601626 Lung cancer, somatic, 211980 Noonan syndrome 3, 609942 Pancreatic carcinoma, somatic, 260350 RAS-associated autoimmune leukoproliferative disorder, 614470 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 |
| LBR | 103 | 98.3% | 91.5% | ?Reynolds syndrome, 613471 Greenberg skeletal dysplasia, 215140 Pelger-Huet anomaly, 169400 Pelger-Huet anomaly with mild skeletal anomalies, 618019 |
| LEMD3 | 122,5 | 99.8% | 98.4% | Buschke-Ollendorff syndrome, 166700 Osteopoikilosis with or without melorheostosis, 166700 |
| LFNG | 117,6 | 92.8% | 87.7% | Spondylocostal dysostosis 3, autosomal recessive, 609813 |
| LHX3 | 116,2 | 96.6% | 96.4% | Pituitary hormone deficiency, combined, 3, 221750 |
| LHX4 | 131,2 | 100.0% | 100.0% | Pituitary hormone deficiency, combined, 4, 262700 |
| LIFR | 110,3 | 99.7% | 97.4% | Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 |
| LMX1B | 146,6 | 99.9% | 98.5% | Nail-patella syndrome, 161200 |
| LONP1 | 148 | 100.0% | 100.0% | CODAS syndrome, 600373 |
| LRP4 | 128 | 99.7% | 99.0% | ?Myasthenic syndrome, congenital, 17, 616304 Cenani-Lenz syndactyly syndrome, 212780 Sclerosteosis 2, 614305 |
| LRP5 | 168,1 | 99.8% | 98.7% | Exudative vitreoretinopathy 4, 601813 Hyperostosis, endosteal, 144750 Osteopetrosis, autosomal dominant 1, 607634 Osteoporosis-pseudoglioma syndrome, 259770 Osteosclerosis, 144750 Polycystic liver disease 4 with or without kidney cysts, 617875 van Buchem disease, type 2, 607636 [Bone mineral density variability 1], 601884 {Osteoporosis}, 166710 |

| | | | | |
|--------|-------|--------|--------|---|
| LRRK1 | 145,2 | 99.5% | 97.9% | No OMIM phenotype Osteosclerotic metaphyseal dysplasia (Iida (2016) J Med Genet 53,568) ?Parkinson disease (Schulte (2013) Neurogenetics epub,epub) |
| LTBP2 | 112,9 | 99.9% | 99.3% | ?Weill-Marchesani syndrome 3, recessive, 614819 Glaucoma 3, primary congenital, D, 613086 Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 |
| LTBP3 | 147,5 | 100.0% | 99.6% | Dental anomalies and short stature, 601216 Geleophysic dysplasia 3, 617809 |
| LZTR1 | 143,6 | 100.0% | 99.7% | Noonan syndrome 10, 616564 Noonan syndrome 2, 605275 {Schwannomatosis-2, susceptibility to}, 615670 |
| MAN2B1 | 128,6 | 99.9% | 98.6% | Mannosidosis, alpha-, types I and II, 248500 |
| MANBA | 118,3 | 99.5% | 97.5% | Mannosidosis, beta, 248510 |
| MAP2K1 | 92,3 | 99.5% | 96.3% | Cardiofaciocutaneous syndrome 3, 615279 |
| MAP2K2 | 124,2 | 98.5% | 94.1% | Cardiofaciocutaneous syndrome 4, 615280 |
| MAP3K7 | 118,4 | 99.9% | 99.3% | Cardiospondylocarpofacial syndrome, 157800 Frontometaphyseal dysplasia 2, 617137 |
| MATN3 | 99,6 | 86.5% | 84.5% | ?Spondyloepimetaphyseal dysplasia, 608728 Epiphyseal dysplasia, multiple, 5, 607078 {Osteoarthritis susceptibility 2}, 140600 |
| MEOX1 | 105 | 99.9% | 97.4% | Klippel-Feil syndrome 2, 214300 |
| MESP2 | 128 | 97.0% | 94.9% | Spondylocostal dysostosis 2, autosomal recessive, 608681 |
| MGP | 134,2 | 98.7% | 94.6% | Keutel syndrome, 245150 |
| MIR140 | NC | NC | NC | No OMIM phenotype |
| MMP13 | 112,5 | 93.4% | 92.1% | Metaphyseal anadysplasia 1, 602111 Metaphyseal dysplasia, Spahr type, 250400 Spondyloepimetaphyseal dysplasia, Missouri type, 602111 |
| MMP14 | 148 | 100.0% | 99.7% | ?Winchester syndrome, 277950 |
| MMP2 | 154,2 | 100.0% | 100.0% | Multicentric osteolysis, nodulosis, and arthropathy, 259600 |
| MMP9 | 143,9 | 100.0% | 99.1% | Metaphyseal anadysplasia 2, 613073 |
| MTAP | 96 | 98.9% | 93.4% | Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 |

| | | | | |
|--------|-------|--------|--------|---|
| MYH3 | 94,1 | 99.9% | 98.3% | Arthrogryposis, distal, type 2A (Freeman-Sheldon), 193700 Arthrogryposis, distal, type 2B (Sheldon-Hall), 601680 Arthrogryposis, distal, type 8, 178110 |
| NAGLU | 117,7 | 97.1% | 94.1% | ?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 |
| NANS | 97,2 | 99.9% | 98.4% | Spondyloepimetaphyseal dysplasia, Camera-Genevieve type, 610442 |
| NBAS | 138,5 | 99.9% | 99.1% | Infantile liver failure syndrome 2, 616483 Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 |
| NEK1 | 115,9 | 99.7% | 98.1% | Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 {Amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 |
| NEK9 | 118,9 | 99.8% | 98.2% | ?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262 Lethal congenital contracture syndrome 10, 617022 Nevus comedonicus, somatic, 617025 |
| NEU1 | 141,3 | 99.3% | 96.4% | Sialidosis, type I, 256550 Sialidosis, type II, 256550 |
| NIN | 127 | 99.9% | 99.4% | ?Seckel syndrome 7, 614851 |
| NKX3-2 | 138,4 | 100.0% | 99.8% | Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 |
| NOTCH2 | 123,7 | 100.0% | 99.6% | Alagille syndrome 2, 610205 Hajdu-Cheney syndrome, 102500 |
| NPPC | 133 | 100.0% | 100.0% | No OMIM phenotype |
| NPR2 | 144,1 | 100.0% | 99.4% | Acromesomelic dysplasia, Maroteaux type, 602875 Epiphyseal chondrodysplasia, Miura type, 615923 Short stature with nonspecific skeletal abnormalities, 616255 |
| NRAS | 145,5 | 100.0% | 100.0% | ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 Colorectal cancer, somatic, 114500 Epidermal nevus, somatic, 162900 Melanocytic nevus syndrome, congenital, somatic, 137550 Neurocutaneous melanosis, somatic, 249400 Noonan syndrome 6, 613224 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 Thyroid carcinoma, follicular, somatic, 188470 |
| NXN | 122,6 | 100.0% | 100.0% | No OMIM phenotype |
| OBSL1 | 147,2 | 100.0% | 99.8% | 3-M syndrome 2, 612921 |

| | | | | |
|--------|-------|--------|--------|---|
| OFD1 | 51,9 | 85.8% | 70.8% | ?Retinitis pigmentosa 23, 300424 Joubert syndrome 10, 300804 Orofaciodigital syndrome I, 311200 Simpson-Golabi-Behmel syndrome, type 2, 300209 |
| ORC1 | 90,3 | 99.9% | 98.7% | Meier-Gorlin syndrome 1, 224690 |
| ORC4 | 73,6 | 98.1% | 92.0% | Meier-Gorlin syndrome 2, 613800 |
| ORC6 | 127,6 | 100.0% | 99.9% | Meier-Gorlin syndrome 3, 613803 |
| OSTM1 | 109,3 | 98.2% | 92.5% | Osteopetrosis, autosomal recessive 5, 259720 |
| OTX2 | 127,4 | 100.0% | 99.3% | Microphthalmia, syndromic 5, 610125 Pituitary hormone deficiency, combined, 6, 613986 Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 |
| P3H1 | 129,3 | 100.0% | 100.0% | Osteogenesis imperfecta, type VIII, 610915 |
| P4HB | 108,7 | 94.6% | 93.8% | Cole-Carpenter syndrome 1, 112240 |
| PAM16 | 64,5 | 66.4% | 65.3% | Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type, 613320 |
| PAPPA2 | 140,1 | 100.0% | 99.7% | No OMIM phenotype Short stature (Dauber (2016) EMBO Mol Med epub,epub) |
| PAPSS2 | 103,8 | 99.7% | 97.7% | Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 |
| PCNT | 115,4 | 99.7% | 97.7% | Microcephalic osteodysplastic primordial dwarfism, type II, 210720 |
| PCYT1A | 95,6 | 97.9% | 94.4% | Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 |
| PDE4D | 102,7 | 95.8% | 94.4% | Acrodysostosis 2, with or without hormone resistance, 614613 |
| PEX5 | 107,9 | 100.0% | 99.2% | Peroxisome biogenesis disorder 2A (Zellweger), 214110 Peroxisome biogenesis disorder 2B, 202370 Rhizomelic chondrodysplasia punctata, type 5, 616716 |
| PEX7 | 111 | 91.2% | 89.3% | Peroxisome biogenesis disorder 9B, 614879 Rhizomelic chondrodysplasia punctata, type 1, 215100 |
| PHEX | 107,9 | 99.8% | 98.6% | Hypophosphatemic rickets, X-linked dominant, 307800 |
| PHGDH | 106,6 | 100.0% | 99.3% | Neu-Laxova syndrome 1, 256520 Phosphoglycerate dehydrogenase deficiency, 601815 |
| PIK3R1 | 124,3 | 99.9% | 98.9% | ?Agammaglobulinemia 7, autosomal recessive, 615214 Immunodeficiency 36, 616005 SHORT syndrome, 269880 |
| PISD | 160,3 | 100.0% | 99.9% | No OMIM phenotype |
| PITX1 | 174,5 | 98.9% | 96.0% | Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 Liebenberg syndrome, 186550 |

| | | | | |
|---------|-------|--------|--------|--|
| PITX2 | 164,8 | 100.0% | 99.5% | Anterior segment dysgenesis 4, 137600 Axenfeld-Rieger syndrome, type 1, 180500 Ring dermoid of cornea, 180550 |
| PKDCC | 86,8 | 94.7% | 87.9% | No OMIM phenotype |
| PLEKHM1 | 127,8 | 100.0% | 99.9% | ?Osteopetrosis, autosomal recessive 6, 611497 Osteopetrosis, autosomal dominant 3, 618107 |
| PLK4 | 149,7 | 99.8% | 98.2% | Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 |
| PLOD2 | 121,3 | 99.6% | 97.3% | Bruck syndrome 2, 609220 |
| PLS3 | 116,9 | 96.9% | 95.3% | Bone mineral density QTL18, osteoporosis, 300910 |
| POC1A | 112,9 | 100.0% | 100.0% | Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 |
| POP1 | 120,1 | 100.0% | 99.4% | Anauxetic dysplasia 2, 617396 |
| POR | 175,5 | 99.2% | 97.1% | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 |
| POU1F1 | 109,1 | 99.9% | 98.2% | Pituitary hormone deficiency, combined, 1, 613038 |
| PPIB | 106,9 | 100.0% | 100.0% | Osteogenesis imperfecta, type IX, 259440 |
| PPP1CB | 113,1 | 100.0% | 99.1% | Noonan syndrome-like disorder with loose anagen hair 2, 617506 |
| PRKAR1A | 79,4 | 98.6% | 92.6% | Acrodysostosis 1, with or without hormone resistance, 101800 Adrenocortical tumor, somatic, 0 Carney complex, type 1, 160980 Myxoma, intracardiac, 255960 Pigmented nodular adrenocortical disease, primary, 1, 610489 |
| PROKR2 | 223 | 100.0% | 100.0% | Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 |
| PROP1 | 96,9 | 92.5% | 83.7% | Pituitary hormone deficiency, combined, 2, 262600 |
| PSAT1 | 42,8 | 90.3% | 72.5% | ?Phosphoserine aminotransferase deficiency, 610992 Neu-Laxova syndrome 2, 616038 |
| PTDSS1 | 112 | 100.0% | 99.9% | Lenz-Majewski hyperostotic dwarfism, 151050 |
| PTH1R | 106,6 | 100.0% | 99.1% | Chondrodysplasia, Blomstrand type, 215045 Eiken syndrome, 600002 Failure of tooth eruption, primary, 125350 Metaphyseal chondrodysplasia, Murk Jansen type, 156400 |
| PTPN11 | 78,3 | 98.6% | 90.7% | LEOPARD syndrome 1, 151100 Leukemia, juvenile myelomonocytic, somatic, 607785 Metachondromatosis, 156250 Noonan syndrome 1, 163950 |
| RAB33B | 191,3 | 100.0% | 100.0% | Smith-McCort dysplasia 2, 615222 |
| RAC3 | 121 | 98.3% | 94.6% | No OMIM phenotype |

| | | | | |
|----------|-------|--------|--------|---|
| RAF1 | 108,3 | 100.0% | 99.9% | Cardiomyopathy, dilated, 1NN, 615916 LEOPARD syndrome 2, 611554 Noonan syndrome 5, 611553 |
| RASGRP2 | 102,5 | 100.0% | 99.7% | ?Bleeding disorder, platelet-type, 18, 615888 |
| RBM8A | 87,4 | 99.8% | 97.4% | Thrombocytopenia-absent radius syndrome, 274000 |
| RBPJ | 70,7 | 96.3% | 87.0% | Adams-Oliver syndrome 3, 614814 |
| RECQL4 | 159,9 | 100.0% | 99.8% | Baller-Gerold syndrome, 218600 RAPADILINO syndrome, 266280 Rothmund-Thomson syndrome, 268400 |
| RIPPLY2 | 78,7 | 100.0% | 98.7% | ?Spondylocostal dysostosis 6, 616566 |
| RIT1 | 139,2 | 100.0% | 100.0% | Noonan syndrome 8, 615355 |
| RMRP | NC | NC | NC | Anauxetic dysplasia 1, 607095 Cartilage-hair hypoplasia, 250250 Metaphyseal dysplasia without hypotrichosis, 250460 |
| RNPC3 | 41,6 | 88.8% | 68.7% | ?Growth hormone deficiency, isolated, type V, 618160 |
| RNU4ATAC | NC | NC | NC | Microcephalic osteodysplastic primordial dwarfism, type I, 210710 Roifman syndrome, 616651 |
| ROR2 | 160,6 | 100.0% | 99.7% | Brachydactyly, type B1, 113000 Robinow syndrome, autosomal recessive, 268310 |
| RPGRIP1L | 123,4 | 96.7% | 95.4% | COACH syndrome, 216360 Joubert syndrome 7, 611560 Meckel syndrome 5, 611561 |
| RPL10 | 65,6 | 97.1% | 86.9% | Mental retardation, X-linked, syndromic, 35, 300998 {Autism, susceptibility to, X-linked 5}, 300847 |
| RRAS | 125,6 | 100.0% | 99.1% | No OMIM phenotype |
| RSPRY1 | 142 | 100.0% | 99.9% | Spondyloepimetaphyseal dysplasia, Faden-Alkuraya type, 616723 |
| RUNX2 | 102,8 | 73.4% | 72.2% | Cleidocranial dysplasia, 119600 Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 |
| SBDS | 166,2 | 100.0% | 100.0% | Shwachman-Diamond syndrome, 260400 {Aplastic anemia, susceptibility to}, 609135 |
| SCARF2 | 104,8 | 99.5% | 95.7% | Van den Ende-Gupta syndrome, 600920 |
| SEC24D | 126,3 | 99.9% | 99.5% | Cole-Carpenter syndrome 2, 616294 |
| SERPINF1 | 104 | 100.0% | 99.9% | Osteogenesis imperfecta, type VI, 613982 |

| | | | | |
|----------|-------|--------|--------|---|
| SERPINH1 | 195,8 | 100.0% | 99.6% | Osteogenesis imperfecta, type X, 613848 {Preterm premature rupture of the membranes, susceptibility to}, 610504 |
| SGMS2 | 148,2 | 100.0% | 100.0% | No OMIM phenotype |
| SGSH | 140,2 | 97.6% | 94.7% | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 |
| SH3PXD2B | 161,4 | 100.0% | 99.9% | Frank-ter Haar syndrome, 249420 |
| SHOC2 | 139,6 | 99.9% | 99.4% | Noonan-like syndrome with loose anagen hair, 607721 |
| SHOX | 35,9 | 82.5% | 67.2% | Langer mesomelic dysplasia, 249700 Leri-Weill dyschondrosteosis, 127300 Short stature, idiopathic familial, 300582 |
| SLC10A7 | 111 | 99.9% | 99.2% | Short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 |
| SLC17A5 | 137,7 | 99.8% | 96.1% | Salla disease, 604369 Sialic acid storage disorder, infantile, 269920 |
| SLC25A24 | 128,9 | 99.6% | 99.1% | Fontaine progeroid syndrome, 612289 |
| SLC26A2 | 205,1 | 100.0% | 99.9% | Achondrogenesis Ib, 600972 Atelosteogenesis, type II, 256050 De la Chapelle dysplasia, 256050 Diastrophic dysplasia, 222600 Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 Epiphyseal dysplasia, multiple, 4, 226900 |
| SLC29A3 | 173,3 | 100.0% | 99.5% | Histiocytosis-lymphadenopathy plus syndrome, 602782 |
| SLC34A3 | 141,1 | 99.9% | 99.0% | Hypophosphatemic rickets with hypercalciuria, 241530 |
| SLC35D1 | 125 | 99.5% | 97.2% | Schneckenbecken dysplasia, 269250 |
| SLC39A13 | 145,1 | 100.0% | 99.9% | Ehlers-Danlos syndrome, spondylodysplastic type, 3, 612350 |
| SLCO2A1 | 97,7 | 99.9% | 98.2% | Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 |
| SLCO5A1 | 159,4 | 99.7% | 98.3% | No OMIM phenotype Mesomelia-synostoses syndrome (Isidor (2010) Am J Hum Genet 87,95) |
| SMAD4 | 108,9 | 100.0% | 99.9% | Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 Myhre syndrome, 139210 Pancreatic cancer, somatic, 260350 Polyposis, juvenile intestinal, 174900 |
| SMARCAL1 | 113,2 | 100.0% | 99.6% | Schimke immunoosseous dysplasia, 242900 |
| SNRPB | 77,7 | 99.9% | 97.6% | Cerebrocostomandibular syndrome, 117650 |
| SNX10 | 131,4 | 96.2% | 95.7% | Osteopetrosis, autosomal recessive 8, 615085 |
| SOS1 | 102 | 99.6% | 97.4% | ?Fibromatosis, gingival, 1, 135300 Noonan syndrome 4, 610733 |

| | | | | |
|---------|-------|--------|--------|--|
| SOS2 | 99,7 | 99.7% | 97.9% | Noonan syndrome 9, 616559 |
| SOST | 182,9 | 100.0% | 99.6% | Craniodiaphyseal dysplasia, autosomal dominant, 122860 Sclerosteosis 1, 269500 Van Buchem disease, 239100 |
| SOX2 | 230 | 100.0% | 100.0% | Microphthalmia, syndromic 3, 206900 Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 |
| SOX3 | 74 | 97.7% | 92.9% | Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 Panhypopituitarism, X-linked, 312000 |
| SOX9 | 159,9 | 100.0% | 100.0% | Acampomelic campomelic dysplasia, 114290 Campomelic dysplasia, 114290 Campomelic dysplasia with autosomal sex reversal, 114290 |
| SP7 | 148,4 | 100.0% | 99.3% | Osteogenesis imperfecta, type XII, 613849 |
| SPARC | 134,3 | 100.0% | 100.0% | Osteogenesis imperfecta, type XVII, 616507 |
| SPECC1L | 127,5 | 100.0% | 99.8% | ?Facial clefting, oblique, 1, 600251 Hypertelorism, Teebi type, 145420 Opitz GBBB syndrome, type II, 145410 |
| SPINK5 | 128 | 99.9% | 99.5% | Netherton syndrome, 256500 |
| SPR | 145,7 | 100.0% | 99.8% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 |
| SPRED1 | 146,5 | 99.8% | 98.8% | Legius syndrome, 611431 |
| SRCAP | 153 | 100.0% | 99.6% | Floating-Harbor syndrome, 136140 |
| STAT3 | 103,2 | 100.0% | 99.0% | Autoimmune disease, multisystem, infantile-onset, 1, 615952 Hyper-IgE recurrent infection syndrome, 147060 |
| STAT5B | 114,1 | 99.8% | 97.8% | Growth hormone insensitivity with immunodeficiency, 245590 Leukemia, acute promyelocytic, somatic, 102578 |
| SULF1 | 135,6 | 99.9% | 98.8% | No OMIM phenotype Mesomelia-synostoses syndrome (Isidor (2010) Am J Hum Genet 87,95) ?Hyperinsulinism (Proverbio (2013) PLoS One 8,e68740) |
| SUMF1 | 89,7 | 99.7% | 96.8% | Multiple sulfatase deficiency, 272200 |
| TAPT1 | 89,2 | 97.9% | 92.2% | Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinck type, 616897 |
| TBCE | 116,4 | 98.7% | 94.7% | Encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 Kenny-Caffey syndrome, type 1, 244460 |
| TBX15 | 106,3 | 100.0% | 99.7% | Cousin syndrome, 260660 |
| TBX4 | 175,9 | 99.5% | 97.5% | Ischiocoxopodopatellar syndrome, 147891 |

| | | | | |
|-----------|-------|--------|--------|---|
| TBX6 | 124,4 | 99.7% | 96.5% | Spondylocostal dysostosis 5, 122600 |
| TBXAS1 | 128,8 | 100.0% | 100.0% | ?Thromboxane synthase deficiency, 614158 Ghosal hematodiaphyseal syndrome, 231095 |
| TCIRG1 | 131,4 | 99.2% | 96.6% | Osteopetrosis, autosomal recessive 1, 259700 |
| TCTEX1D2 | 123,6 | 100.0% | 99.4% | Short-rib thoracic dysplasia 17 with or without polydactyly, 617405 |
| TCTN2 | 122,4 | 99.9% | 99.0% | ?Meckel syndrome 8, 613885 Joubert syndrome 24, 616654 |
| TCTN3 | 116,3 | 100.0% | 99.9% | Joubert syndrome 18, 614815 Orofaciodigital syndrome IV, 258860 |
| TGFB1 | 102,1 | 100.0% | 99.6% | Camurati-Engelmann disease, 131300 Inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 {Cystic fibrosis lung disease, modifier of}, 219700 |
| TMEM165 | 148,2 | 100.0% | 99.8% | Congenital disorder of glycosylation, type IIk, 614727 |
| TMEM216 | 88 | 99.7% | 95.7% | Joubert syndrome 2, 608091 Meckel syndrome 2, 603194 |
| TMEM231 | 101,1 | 100.0% | 99.3% | Joubert syndrome 20, 614970 Meckel syndrome 11, 615397 |
| TMEM38B | 107,9 | 100.0% | 99.0% | Osteogenesis imperfecta, type XIV, 615066 |
| TNFRSF11A | 131 | 96.1% | 95.2% | Osteolysis, familial expansile, 174810 Osteopetrosis, autosomal recessive 7, 612301 {Paget disease of bone 2, early-onset}, 602080 |
| TNFRSF11B | 172,4 | 100.0% | 100.0% | Paget disease of bone 5, juvenile-onset, 239000 |
| TNFSF11 | 129,8 | 100.0% | 100.0% | Osteopetrosis, autosomal recessive 2, 259710 |
| TONSL | 125,7 | 100.0% | 99.5% | No OMIM phenotype Pancreatic cancer (Smith (2015) Cancer Lett epub,epub) ?Schizophrenia (Fromer (2014) Nature 506, 179) |
| TRAPPC2 | 59,2 | 86.5% | 67.4% | Spondyloepiphyseal dysplasia tarda, 313400 |
| TRIP11 | 90,9 | 97.5% | 92.6% | Achondrogenesis, type IA, 200600 Osteochondrodysplasia, 184260 |
| TRPS1 | 154 | 100.0% | 99.9% | Trichorhinophalangeal syndrome, type I, 190350 Trichorhinophalangeal syndrome, type III, 190351 |

| | | | | |
|--------|-------|--------|--------|---|
| TRPV4 | 138,4 | 100.0% | 99.8% | ?Avascular necrosis of femoral head, primary, 2, 617383 Brachyolmia type 3, 113500 Digital arthropathy-brachydactyly, familial, 606835 Hereditary motor and sensory neuropathy, type IIc, 606071 Metatropic dysplasia, 156530 Parastremmatic dwarfism, 168400 Scapuloperoneal spinal muscular atrophy, 181405 SED, Maroteaux type, 184095 Spinal muscular atrophy, distal, congenital nonprogressive, 600175 Spondylometaphyseal dysplasia, Kozlowski type, 184252 [Sodium serum level QTL 1], 613508 |
| TTC21B | 119,5 | 99.7% | 98.8% | Nephronophthisis 12, 613820 Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 |
| UFSP2 | 130,7 | 100.0% | 99.5% | ?Hip dysplasia, Beukes type, 142669 ?Spondyloepimetaphyseal dysplasia, Di Rocco type, 617974 |
| VDR | 108,8 | 99.1% | 96.0% | ?Osteoporosis, involutinal, 166710 Rickets, vitamin D-resistant, type IIA, 277440 |
| WDR19 | 126,8 | 100.0% | 99.2% | ?Cranioectodermal dysplasia 4, 614378 ?Short-rib thoracic dysplasia 5 with or without polydactyly, 614376 Nephronophthisis 13, 614377 Senior-Loken syndrome 8, 616307 |
| WDR34 | 116,1 | 100.0% | 100.0% | Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 |
| WDR35 | 141,8 | 99.7% | 98.4% | Cranioectodermal dysplasia 2, 613610 Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 |
| WDR60 | 108,1 | 99.7% | 98.1% | Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 |
| WISP3 | NC | NC | NC | Arthropathy, progressive pseudorheumatoid, of childhood, 208230 Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 |
| WNT1 | 255,8 | 100.0% | 99.8% | Osteogenesis imperfecta, type XV, 615220 {Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 |
| WNT5A | 159 | 100.0% | 100.0% | Robinow syndrome, autosomal dominant 1, 180700 |
| XRCC4 | 143 | 99.9% | 99.0% | Short stature, microcephaly, and endocrine dysfunction, 616541 |
| XYLT1 | 128,1 | 99.9% | 98.2% | Desbuquois dysplasia 2, 615777 {Pseudoxanthoma elasticum, modifier of severity of}, 264800 |
| XYLT2 | 147,5 | 99.7% | 98.1% | Spondyloocular syndrome, 605822 {Pseudoxanthoma elasticum, modifier of severity of}, 264800 |

| | | | | |
|----------|-------|--------|--------|--|
| ZBTB16 | 148,4 | 100.0% | 100.0% | Leukemia, acute promyelocytic, PL2F/RARA type, 0 Skeletal defects, genital hypoplasia, and mental retardation, 612447 |
| ZMPSTE24 | 128,7 | 100.0% | 99.6% | Mandibuloacral dysplasia with type B lipodystrophy, 608612 Restrictive dermopathy, lethal, 275210 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan;43(Database issue):D1079-85.

Median Coverage describes the average number of reads seen across 50 exomes.

% Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.

% Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.

Genes with Median Coverage and % Covered 10x/20x denoting NC are non-coding genes for which coverage statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : May 8th, 2019.

This list is accurate for panel version DG 2.16

Ad 1. "No OMIM phenotype" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors
